Daiichi Sankyo Co., Ltd. ADR (DSNKY) - OTCPK - Current
  • Sep. 27, 2013, 1:14 PM
    • Today's rally in shares of ArQule (ARQL +9.7%) is likely attributable to RBC's Adnan Butt, who Reuters quotes as saying that an upcoming presentation at ESMO could mean another shot for tivantinib in lung cancer.
    • The drug was effectively left for dead (at least as far as NSCLC goes) last October when ARQL and partner Daiichi Sankyo (DSKYF.PK) dropped a Phase 3 trial due to lack of efficacy.
    • New data from that trial "could validate the mechanism of action for the drug and potentially allow a path forward in lung cancer as well," Butt says.
    | Sep. 27, 2013, 1:14 PM
  • Jun. 27, 2013, 3:06 PM

    Portola Pharmaceuticals (PTLA +10.1%) moves up after saying late yesterday that it had entered into a clinical collaboration agreement with Daiichi Sankyo (DSNKY.PK) to conduct a Phase 2 study of its investigational Factor Xa inhibitor antidote PRT4445, or andexanet alfa. The study will at several different doses to reverse the anticoagulant effects of Daiichi Sankyo's edoxaban in healthy volunteers.

    | Jun. 27, 2013, 3:06 PM
  • Jun. 27, 2013, 2:44 PM

    Portola Pharmaceuticals (PTLA +10.1%) moves up after saying late yesterday that it had entered into a clinical collaboration agreement with Daiichi Sankyo (DSNKY.PK) to conduct a Phase 2 study of its investigational Factor Xa inhibitor antidote PRT4445, or andexanet alfa. The study will at several different doses to reverse the anticoagulant effects of Daiichi Sankyo's oral direct Factor Xa inhibitor edoxaban in healthy volunteers.

    | Jun. 27, 2013, 2:44 PM
Company Description
Founded on September 28, 2005 through the merger of Daiichi Pharmaceutical and Sankyo, Daiichi Sankyo delivers innovative products that enhance the lives of millions of people around the world. Our recent successes include the antihypertensive agent olmesartan (Olmetec), launched in 2002 by... More
Country: Japan